Who are Busulfan/Cyclophosphamide's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PCV chemotherapy, Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan, Busulphan plus Cyclophosphamide, Fludarabine, OKT3, Treosulfan, Thiotepa.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/busulfan-cyclophosphamide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Busulfan/Cyclophosphamide — Competitive Intelligence Brief

Busulfan/Cyclophosphamide (Busulfan/Cyclophosphamide) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alkylating agents. Area: Oncology.

marketed Alkylating agents Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Busulfan/Cyclophosphamide (Busulfan/Cyclophosphamide) — Tel-Aviv Sourasky Medical Center. Busulfan and cyclophosphamide are alkylating agents that damage DNA and suppress bone marrow function, used together as a myeloablative conditioning regimen prior to hematopoietic stem cell transplantation.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Busulfan/Cyclophosphamide TARGET	Busulfan/Cyclophosphamide	Tel-Aviv Sourasky Medical Center	marketed	Alkylating agents
PCV chemotherapy	PCV chemotherapy	Hospices Civils de Lyon	phase 3	Chemotherapy regimen (alkylating agents + vinca alkaloid)
Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan	Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan	Dutch Childhood Oncology Group	phase 3	Multi-agent chemotherapy regimen; alkylating agents, antimetabolite, topoisomerase II inhibitor
Busulphan plus Cyclophosphamide	Busulphan plus Cyclophosphamide	Gruppo Italiano Trapianto di Midollo Osseo	phase 3	Alkylating agents
Fludarabine, OKT3, Treosulfan, Thiotepa	Fludarabine, OKT3, Treosulfan, Thiotepa	St. Anna Kinderkrebsforschung	phase 3	Multi-agent conditioning regimen (purine analog, monoclonal antibody, alkylating agents)	dTMP synthase (fludarabine); CD3 (OKT3); DNA (treosulfan, thiotepa)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alkylating agents class)

Gruppo Italiano Trapianto di Midollo Osseo · 1 drug in this class
Tel-Aviv Sourasky Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Busulfan/Cyclophosphamide — Competitive Intelligence Brief. https://druglandscape.com/ci/busulfan-cyclophosphamide. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab